Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound is a modification of the older drug tacrine (Cognex).[1]

Ipidacrine is a reversible acetylcholinesterase inhibitor used in memory disorders of different origins.[2][3][4]

Ipidacrine directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels. Ipidacrine enhances not only choline, but also adrenaline, serotonin, histamine, and oxytocin effects on smooth muscle.[5]

References

  1. ^ Kojima J, Onodera K, Ozeki M, Nakayarna K (1998). "Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent". CNS Drug Reviews. 4 (3): 247–259. doi:10.1111/j.1527-3458.1998.tb00067.x.
  2. ^ Damulin IV, Stepkina DA, Lokshina AB (2011). "[Neuromidin in mixed vascular and Alzheimer's dementia]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 111 (2): 40–3. PMID 21350422.
  3. ^ Pustokhanova LV, Morozova EM (2011). "[Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 111 (4 Pt 2): 23–7. PMID 23120773.
  4. ^ Onodera K, Kojima J, Wachi M (April 1998). "Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task". Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology. 18 (2): 33–7. PMID 9656230.
  5. ^ "Neiromidin Product Information". Archived from the original on 2013-06-13. Retrieved 2013-05-30.